Trial Profile
Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2022
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacodynamics
- 01 Jun 2009 Results published in Arteriosclerosis Thrombosis and Vascular Biology.
- 22 Sep 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Nov 2007 New trial record.